Nova Eye USA Sales Growth Opportunity
Operating Results for H1FY24
FY23 (Audited)
H1 FY24 (unaudited)
Australian dollars ('000'S)
Group
Revenue
Glaucoma AlphaRET Corporate
Group
Glaucoma
AlphaRET Corporate
Group
16,661
364
17,025
10,062
77
10,139
GM
11,392
323
11,715
6,900
40
6,940
68%
69%
Operating
(17,676)
(1,364) (2,225) (21,265)
(9,433)
(473)
(1,213)
(11,119)
expenditure
EBITDA (loss)
(6,284)
(1,041) (2,225) (9,550) (2,533)
(433)
(1,213)
(4,179)
FY23
(Audited)
H1 FY24
(unaudited)
Glaucoma only
USA dollars ('000's)
Commentary on H1FY24 compared with FY23
•
Improved gross margin
Improved ratio of operating expenditure to revenue
shows leverage
Revenue
GM
11,273
6,619
7,548
4,539
67%
69%
Operating
(11,548)
(6,128)
expenditure
EBITDA
(4,000)
(1,589)
ne
nova-eye.com | 24View entire presentation